Compare CZWI & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZWI | TTRX |
|---|---|---|
| Founded | 1938 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.5M | 174.9M |
| IPO Year | 2006 | N/A |
| Metric | CZWI | TTRX |
|---|---|---|
| Price | $22.90 | $5.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 99.5K | 58.2K |
| Earning Date | 04-27-2026 | 05-31-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ 8.96 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.02 | N/A |
| Revenue Next Year | $9.42 | N/A |
| P/E Ratio | $56.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.63 | $2.57 |
| 52 Week High | $22.62 | $6.75 |
| Indicator | CZWI | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 70.56 | 56.63 |
| Support Level | $20.10 | $4.70 |
| Resistance Level | N/A | $6.68 |
| Average True Range (ATR) | 0.82 | 0.56 |
| MACD | 0.20 | -0.06 |
| Stochastic Oscillator | 96.69 | 53.36 |
Citizens Community Bancorp Inc is a bank holding company that offers traditional community banking services to businesses, Agricultural operators, and consumers, including one-to-four-family residential mortgages. it also offers a variety of loan products including commercial real estate loans, commercial and industrial (C&I) loans, agricultural real estate loans, agricultural operating loans, residential mortgages, home equity lines-of-credit, and consumer loans and offers deposit products through its branches, including demand deposits, various savings and money-market accounts and certificates of deposit. The company's sources of funds are deposits; amortization, prepayments, and maturities of outstanding loans; other short - term investments; and funds provided from operations.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.